Novartis and Versant to form biotech venture Borealis Biosciences
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
This project is supported by the Irish Government through IDA Ireland
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated